745 Randomized controlled trial of nocturia in patients with benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with a novel antichorinergic, imidafenacin; GOOD-NIGHT Study

Kuratsukuri, Katsuyuki; Tsujimura, Akira; Akino, Hironobu; Oguchi, Naoki; Kitagawa, Yasuhide; Segawa, Naoki; Tamada, Satoshi; Tuji, H.; Watanabe, A.; Urashima, Mitsuyoshi; Okuyama, Äkïhïko; Uemura, Hirotsugu; Katsuoka, Yoji; Nakatani, Tatsuya; Namiki, Mikio; Fuse, Hideki; Matsuda, Takeru; Yokoyama, Osamu

doi:10.1016/s1569-9056(12)60742-8

Cited by 4 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results demonstrate that treatment with imidafenacin provides both statistically significant and, more importantly, clinically relevant improvements in the OAB symptoms. Furthermore, different trials assessing the effects of imidafenacin on nocturia and sleep quality showed that imidafenacin ameliorates sleep quality and duration in patients with OAB and nocturia [21][22][23][24][25][26]. We conclude that imidafenacin was effective in improving nocturia and sleep disorder in patients with OAB and in decreasing nocturnal urine volume and nocturnal polyuria index in patients with nocturnal polyuria [26], while solifenacin does not.…”

Section: Discussionmentioning

confidence: 87%

Efficacy and safety of imidafenacin for overactive bladder in adult: a systematic review and meta-analysis

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 87%

Efficacy and safety of imidafenacin for overactive bladder in adult: a systematic review and meta-analysis

et al. 2015

View full text Add to dashboard Cite

show abstract

“…At the time of this survey, the results of the TIMES study had already been reported, and additional treatment with an antimuscarinic agent had been suggested as a possible option . However, the efficacy of a combined treatment with an α‐1 blocker and an antimuscarinic agent for Japanese men with OAB and BPH was not demonstrated until after this survey was carried out . Nevertheless, combined treatment with an α‐1 blocker and an antimuscarinic agent was still administered to 320 men with BPH and OAB, accounting for 62.3% of the male OAB patients taking antimuscarinics in the survey (Table ).…”

Section: Discussionmentioning

confidence: 99%

Factors influencing patient satisfaction with antimuscarinic treatment of overactive bladder syndrome: Results of a real‐life clinical study

et al. 2013

View full text Add to dashboard Cite

Abbreviations & AcronymsObjectives: To investigate patient satisfaction with antimuscarinic treatment of overactive bladder syndrome, and to identify factors having a significant influence on satisfaction. Methods: A cross-sectional questionnaire survey was carried out to assess treatment satisfaction among male and female patients with overactive bladder (age ≥20 years) in the Hokuriku district of Japan. The overactive bladder symptom scores, treatment efficacies, adverse events (dry mouth and constipation), and patient satisfaction scores were investigated and compared among patients using different antimuscarinic therapeutics. Results: In total, 977 survey respondents (52.6% men; mean age 73.6 years) received antimuscarinic treatment. The mean overactive bladder symptom score of these patients was 6.17; in addition, 32.3% patients were satisfied with their treatment, but 33.1% were dissatisfied. Factors having a significant influence on treatment satisfaction were sex (men were less satisfied), efficacy, adverse events and the overactive bladder symptom score. Constipation negatively influenced patient satisfaction to a greater extent than did dry mouth. Patient satisfaction varied according to the drug used. Constipation was less severe with the immediate-release-type agents (imidafenacin and oxybutynin) than with the extended-release-type (propiverine, solifenacin or tolterodine). Conclusions: Just one-third of Japanese Hokuriku patients with overactive bladder seem to be satisfied with their antimuscarinic treatment. Patient satisfaction is impaired by poor efficacy and the presence of adverse events; furthermore, constipation should be recognized as an adverse event that negatively influences patient satisfaction to a greater extent than dry mouth. Patient satisfaction differs according to the antimuscarinic agent used, with higher patient satisfaction being associated with less severe constipation.

show abstract

“…A number of studies investigating the effects of imidafenacin on nocturia and sleep quality have been conducted [Takeda et al 2009;Nagaoka et al 2011;Shimizu et al 2011;Kuratsukuri et al 2012], which highlight that imidafenacin is a viable option for improving sleep quality and duration in patients with OAB and nocturia.…”

Section: Other Clinical Trialsmentioning

confidence: 99%

“…The GOOD-NIGHT study investigated the efficacy and tolerability of imidafenacin and α-blocker therapy in men with benign prostatic hyperplasia and OAB [Kuratsukuri et al 2012]. This open-label study in 130 men who had been receiving an α-blocker for at least 4 weeks and were experiencing nocturia randomized patients to an α blocker alone, an α blocker with Table 4.…”

Section: Other Clinical Trialsmentioning

confidence: 99%

“…Discharged from the study due to lack of response, tolerability or other issues (n = 4) Comparator Solifenacin 5 mg/day (n = 20) Discharged from the study due to lack of response, tolerability or other issues (n = 2) imidafenacin 0.1 mg twice daily or an α blocker with imidafenacin 0.1 mg once daily [Kuratsukuri et al 2012]. Adding imidafenacin 0.1 mg twice daily and 0.1 mg once daily (administered in the evening) to α-blocker therapy was associated with a reduction in night-time voiding (p = 0.0014 and 0.0143) and an improvement in Nocturia Quality Of Life Questionnaire scores (p = 0.0013 in imidafenacin 0.1 mg twice daily group only) after 8 weeks of treatment compared with α-blocker therapy alone [Kuratsukuri et al 2012].…”

Section: Studymentioning

confidence: 99%

See 1 more Smart Citation

Experience with imidafenacin in the management of overactive bladder disorder

Takeuchi

Zaitsu

Mikami

2012

Therapeutic Advances in Urology

View full text Add to dashboard Cite

Overactive bladder (OAB) is a chronic syndrome defined by symptoms of urinary urgency with no underlying medical causes. First-line treatment of OAB comprises fluid intake advice and bladder training, supplemented by anticholinergic drugs if necessary. Owing to the chronic nature of OAB, the ideal anticholinergic treatment should have good long-term efficacy and tolerability. There are many anticholinergics available, although some of these are not specific for the bladder and can cause adverse effects such as dry mouth, constipation, blurred vision or cognitive impairment. Imidafenacin (a newer anticholinergic which has been marketed in Japan since 2007) was developed to improve the tolerability of anticholinergic therapy. This article summarizes the pharmacological properties, pharmacokinetics, clinical efficacy and tolerability of imidafenacin in the treatment of OAB. Data from key clinical studies of imidafenacin show that it has a fast onset of action and is effective for the treatment of OAB. It selectively binds to muscarinic receptors in the bladder and is associated with a good safety profile compared with other anticholinergics. The clinical efficacy, superior tolerability and adjustable dosing of imidafenacin make it a good anticholinergic for the treatment of OAB.

show abstract

745 Randomized controlled trial of nocturia in patients with benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with a novel antichorinergic, imidafenacin; GOOD-NIGHT Study

Cited by 4 publications

References 0 publications

Efficacy and safety of imidafenacin for overactive bladder in adult: a systematic review and meta-analysis

Efficacy and safety of imidafenacin for overactive bladder in adult: a systematic review and meta-analysis

Factors influencing patient satisfaction with antimuscarinic treatment of overactive bladder syndrome: Results of a real‐life clinical study

Experience with imidafenacin in the management of overactive bladder disorder

Contact Info

Product

Resources

About